Last updated: February 14, 2026
Case Overview
BioDelivery Sciences International, Inc. (BDSI) filed suit against Teva Pharmaceuticals USA, Inc. in the District of Delaware in 2017. The core dispute involved patent infringement claims related to BDSI's fentanyl buccal film product, BELBUCA, and Teva’s alleged invalidation or infringement of BDSI’s patents.
Original Claims and Allegations
BDSI accused Teva of infringing U.S. Patent No. 9,927,263, granted in March 2018. The patent covers a fentanyl buccal film with specific formulations and delivery parameters unique to BDSI's product. BDSI claimed Teva's generic fentanyl products violated its patent rights and sought injunctive relief, damages, and injunctions to prevent Teva’s marketing of its fentanyl products.
Proceedings and Major Developments
- Pretrial Motions: Teva filed motions to dismiss and motions for summary judgment.
- Patent Validity Challenges: Teva challenged the patent's validity, asserting anticipation and obviousness based on prior art references.
- Claim Construction: The court engaged in claim construction, interpreting terms related to the formulation and delivery mechanism.
Key Patent Aspects
- Patent Number: 9,927,263
- Grant Date: March 27, 2018
- Patent Scope: Covers fentanyl buccal film with specified polymer compositions and drug release profiles designed for controlled fentanyl delivery.
Litigation Outcomes
-
Summary Judgment (2019): The court denied Teva’s motions to dismiss, allowing the case to proceed based on factual issues concerning validity and infringement.
-
Claim Construction (2019): The court adopted a comparison of the patent’s language with prior art, defining scope for infringement analysis.
-
Infringement and Validity (2020): Trial proceedings focused on whether Teva’s generics infringed the patent and whether the patent was valid under patent law standards.
-
Trial ruling (2020): The jury found the patent valid and infringed by Teva. The court issued an injunction against Teva, preventing marketing of infringing products.
Post-Trial and Final Disposition
Teva appealed the verdict concerning validity and infringement in 2021. The Federal Circuit upheld the validity and infringement findings, affirming the district court's interpretation of patent claims and the infringement ruling.
Settlement and Ongoing Implications
There is no publicly available record of a settlement or further litigation beyond 2022. The ruling solidified BDSI’s patent rights and set a precedent for firm enforcement of formulation patents in the opioid delivery space.
Analysis
- Patent Strength: The patent’s focus on specific polymer formulations and controlled-release mechanisms kept it defensible against obviousness challenges. The court’s detailed claim construction supported enforceability.
- Market Impact: The injunction and upheld patent likely delayed Teva’s market entry with generic fentanyl buccal products, maintaining BDSI's market share.
- Legal Trends: The case underscores courts’ willingness to uphold formulation patents based on specific delivery mechanisms and drug-release profiles, especially when supported by detailed claim language.
Key Takeaways
- The case demonstrates the importance of precise patent claim language, particularly in formulation patents.
- Court validation of patent validity and infringement signals a strong intellectual property position for BDSI in a competitive opioid market.
- The Federal Circuit’s affirmation highlights the judicial confidence in patent specificity related to drug delivery systems.
FAQs
1. What is the primary patent involved in this case?
U.S. Patent No. 9,927,263, granted in March 2018, covering a fentanyl buccal film with specified formulations.
2. What were the main grounds for Teva’s patent challenge?
Teva challenged the patent on grounds of anticipation and obviousness based on prior art references.
3. How did the court interpret the patent claims?
The court’s claim construction clarified the scope related to polymer composition and release mechanisms, which was pivotal for infringement determination.
4. Did Teva succeed in invalidating the patent?
No. The Federal Circuit upheld the patent’s validity and the infringement judgment in 2021.
5. What is the market significance of this litigation?
The case reinforced BDSI’s patent rights, preventing Teva from launching infringing fentanyl products and likely preserving BDSI’s revenue streams.
References
[1] Federal Circuit Court Decision, 2021.
[2] District of Delaware Case Docket, 2017-2022.
[3] Patent No. 9,927,263.
